Risperidone Use in the Treatment of Behavioral Symptoms in Children with Autism

West, Lis; Waldrop, Julee
November 2006
Pediatric Nursing;Nov/Dec2006, Vol. 32 Issue 6, p545
Academic Journal
The overall goal of autism treatment is to help the individual function normally or near normal in society (NICHD, 2004). Children and adolescents with autism can display disruptive behaviors, which has created challenges and barriers for teachers, caretakers, and medical professionals. In an attempt to control these behaviors, medical providers are prescribing psychotropic drugs that have not been approved by the United States Food and Drug Administration for the treatment of autism in children. Conventional neuroleptics have been used to treat the more aggressive and violent behaviors associated with autism, but many healthcare professionals and families consider their side effects unacceptable. As a result, atypical antipsychotic drugs, such as risperidone, are being studied as off-label medications to treat autism because of their increased safety and efficacy over conventional neuroleptics. This article will discuss the use of risperidone as a potentially safe and effective treatment for disruptive behavioral symptoms in children with autism.


Related Articles

  • Risperidone.  // Reactions Weekly;6/11/2011, Issue 1355, p30 

    The article describes the case of a 28-year-old woman with androgen insensitivity syndrome who developed extrapyramidal symptoms while undergoing risperidone therapy for schizophrenia.

  • Risperidone.  // Reactions Weekly;6/11/2011, Issue 1355, p30 

    The article describes two cases of patients who developed intraoperative floppy iris syndrome (IFIS) while undergoing risperidone therapy.

  • Risperidone.  // Reactions Weekly;5/8/2010, Issue 1300, p45 

    The article describes the case of a 13-year-old girl with new-onset psychotic disorder who developed hyperprolactinaemia and extrapyramidal symptoms while undergoing risperidone therapy.

  • Risperidone for irritability associated with autism.  // WHO Drug Information;2006, Vol. 20 Issue 4, p271 

    The article reports that risperidone orally disintegrating tablets have been approved by the U.S. Food and Drug Administration. The drug is an adult antipsychotic for the treatment of irritability in autistic children and adolescents. It is the first one to get the approval to treat behaviors...

  • First Drug to Treat Irritability Associated With Autism.  // FDA Consumer;Jan/Feb2007, Vol. 41 Issue 1, p4 

    The article reports on the approval of Risperdal orally disintegrating tablets, an adult antipsychotic drug, for the symptomatic treatment of irritability in autistic children and adolescents by Food and Drug Administration (FDA) in the U.S. The approval is the first for the use of a drug to...

  • Boxed warning now required for antiphychotics for elderly with dementia.  // Primary Care Reports;Aug2008 Pharmacology Watch, p1 

    This article reports on a policy issued by the U.S. Food and Drug Administration in 2008 requiring a boxed warning for conventional antipsychotics. The policy concerns with an increased risk of mortality in elderly patients treated for dementia-elated psychosis. The policy expands the warning on...

  • Warning Regarding Topical Anesthetics.  // Internal Medicine Alert;3/15/2009 Pharmacology Watch, p1 

    The article offers updates related to pharmacology in the U.S. The U.S. Department of Food and Drug Administration warned the public about the life-threatening side effects of topical anesthetics. Both atypical and typical antipsychotic medications can increase the incidence of sudden cardiac...

  • Study: Parkinson's drug warnings ignored. Gustafson, Mary // McKnight's Long-Term Care News;Sep2011, Vol. 32 Issue 9, p6 

    The article reports on the study conducted by University of Pennsylvania researchers which indicates that many Parkinson's disease patients are taking antipsychotic medication in spite of the warnings from the U.S. Food and Drug Administration on the risk of harm it poses.

  • FDA: Seroquel sales aid is misleading. S. M. // Medical Marketing & Media;Jan2007, Vol. 42 Issue 1, p26 

    The article reports on the official prohibition of AstraZeneca PLC's sales aid to market its antipsychotic medication Seroquel as mandated by the U.S. Food and Drug Administration (FDA). The order was sent by FDA's Division of Drug Marketing, Advertising & Communications through a letter. It...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics